Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Sven H. Loosen, Joao Gorgulho, Markus S. Jördens, Maximilian Schulze‐Hagen, Fabian Beier, Mihael Vucur, Anne T. Schneider, Christiane Koppe, Alexander Mertens, Jakob Nikolas Kather, Frank Tacke, Verena Keitel, Tim H. Brümmendorf, Christoph Roderburg, Tom LueddeFrontiers in Oncology 2021 · DOI

Abstract

Our data suggest that measurements of suPAR serum levels are a previously unknown, easily accessible tool to predict individual treatment response and outcome to ICI therapy. Circulating suPAR might therefore be implemented into stratification algorithms to identify the ideal candidates for ICI treatment.

Introduction

Immune checkpoint inhibitors (ICIs), such as nivolumab and pembrolizumab, have fundamentally changed the landscape of oncology. However, these therapies are not universally effective; only a subset of patients experiences durable clinical benefits, while others may suffer from significant side effects without therapeutic gain. Current predictive markers, including PD-L1 expression and Tumor Mutational Burden (TMB), often require invasive tissue biopsies that may not fully represent the systemic immune environment. Consequently, there is a pressing need for non-invasive "liquid biopsy" tools to identify patients most likely to benefit from immunotherapy.

This study investigates the role of soluble urokinase plasminogen activator receptor (suPAR) as a potential biomarker. suPAR is a cleavage product of a receptor expressed on various immune cells, and its elevated levels typically reflect a state of chronic systemic inflammation or immune exhaustion.

Methods

In an observational cohort study conducted at University Hospital RWTH Aachen, researchers recruited 87 patients with advanced-stage solid tumors scheduled for ICI therapy. The cohort included patients with non-small cell lung cancer (NSCLC, 36.8%), malignant melanoma (14.9%), urothelial cancer (13.8%), and other gastrointestinal malignancies. A control group of 32 healthy blood donors was also included for comparison.

Serum suPAR levels were measured using a commercial enzyme-linked immunosorbent assay (ELISA) at baseline (before the first dose) and at two subsequent intervals during treatment. Tumor response was evaluated at three, six, and twelve months using RECIST v1.1 criteria. Statistical analyses, including ROC curve modeling and multivariate Cox-regression, were employed to determine the prognostic value of suPAR independent of other clinical variables.

Results

suPAR as a Cancer Biomarker

Baseline suPAR levels were significantly higher in cancer patients compared to healthy controls (median 5.36 ng/ml vs. 1.55 ng/ml, p < 0.001). Importantly, baseline suPAR levels were largely independent of clinical characteristics such as tumor stage (UICC III vs. IV), ICI regimen, previous treatments, performance status (ECOG), sex, or smoking status.

Baseline suPAR levels across different clinical cohorts. (A) Comparison between healthy controls and cancer patients. (B-H) suPAR levels stratified by tumor stage, entity, ICI regimen, previous treatment, ECOG status, sex, and smoking status.

Predicting Survival and Response

The study identified an optimal prognostic cut-off of 4.86 ng/ml. Patients with baseline suPAR levels below this threshold demonstrated significantly better outcomes:

  • Overall Survival (OS): Patients with low suPAR (<4.86 ng/ml) had a median OS of 705 days, whereas those with high suPAR (>4.86 ng/ml) had a median OS of only 160 days.
  • Disease Control: Low baseline suPAR was a strong predictor of achieving disease control (tumor shrinkage or stability) at the 3-month mark.

The irAE Paradox and Dynamic Monitoring

Interestingly, lower baseline suPAR levels were associated with a higher incidence of immune-related adverse events (irAEs). In the context of ICI therapy, the occurrence of irAEs often correlates with a robust immune response against the tumor. Furthermore, suPAR levels remained relatively stable during the initial cycles of therapy, indicating that the baseline immune state is the primary determinant of treatment success.

Discussion

The findings suggest that high baseline suPAR levels indicate a state of systemic immune exhaustion that hinders the efficacy of ICIs. Conversely, low suPAR levels identify a "primed" immune system more capable of responding to checkpoint blockade.

While this "basket" study suggests suPAR is a pan-cancer marker, certain limitations exist. The lack of a non-ICI control group makes it difficult to definitively state whether suPAR is specific to immunotherapy response or a general marker of cancer progression. Future research should focus on larger, disease-specific cohorts and explore the underlying molecular mechanisms linking suPAR to ICI resistance.

Conclusion

Serum suPAR is a potent, easily accessible biomarker for predicting response and survival in patients undergoing ICI therapy. Integrating suPAR measurements into clinical stratification algorithms could significantly improve patient selection and personalized treatment planning in oncology.

Summary updated

Abstract

Our data suggest that measurements of suPAR serum levels are a previously unknown, easily accessible tool to predict individual treatment response and outcome to ICI therapy. Circulating suPAR might therefore be implemented into stratification algorithms to identify the ideal candidates for ICI treatment.
BibTeX
@inproceedings{loosen2021serum,
  author = {Sven H. Loosen and Joao Gorgulho and Markus S. Jördens and Maximilian Schulze‐Hagen and Fabian Beier and Mihael Vucur and Anne T. Schneider and Christiane Koppe and Alexander Mertens and Jakob Nikolas Kather and Frank Tacke and Verena Keitel and Tim H. Brümmendorf and Christoph Roderburg and Tom Luedde},
  title = {{Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.646883},
}
Figure